Linked Life Data

12428191

Source:http://linkedlifedata.com/resource/pubmed/id/12428191

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
27-28
pubmed:dateCreated
2002-11-12
pubmed:abstractText
Immunocompromised cancer patients are at elevated risk for serious viral disease. The introduction into clinical use of potent antiviral agents and of rapid diagnostic tests resulted in the development of efficient management strategies for infections due to herpes simplex virus, varicellazoster virus, and cytomegalovirus. The emergence of herpesvirus resistance to acyclovir, ganciclovir, cidofovir, or foscarnet represents an important challenge. The new neuraminidase inhibitors zanamivir and oseltamivir are efficacious in the treatment of influenza in otherwise healthy adults, and need to be investigated among immunodeficient patients with malignancy. Preliminary data on pleconaril, a first broad-spectrum anti-picornaviral compound, are promising.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1424-7860
pubmed:author
pubmed:issnType
Print
pubmed:day
13
pubmed:volume
132
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
374-8
pubmed:dateRevised
2011-2-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Management of viral infections in immunocompromised cancer patients.
pubmed:affiliation
Division of Medicine, Hôpital régional, Porrentruy, Switzerland. pierre.reusser@cgh.ch
pubmed:publicationType
Journal Article, Review